Current Report Filing (8-k)
January 28 2020 - 10:17AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): January 27, 2020
InspireMD,
Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-35731
|
|
26-2123838
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
4
Menorat Hamaor St.
Tel
Aviv, Israel
|
|
6744832
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(888)
776-6804
(Registrant’s
telephone number, including area code)
N/A
(Former
Name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
|
NSPR
|
|
NYSE
American
|
Warrants,
exercisable for one share of Common Stock
|
|
NSPR.WS
|
|
NYSE
American
|
Series
B Warrants, exercisable for one share of Common Stock
|
|
NSPR.WSB
|
|
NYSE
American
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 Other Events.
On
January 27, 2020, InspireMD, Inc. issued a press release announcing that its CGuard™ Carotid Embolic Prevention System (“EPS”)
will be featured in a live case transmission at the Leipzig Interventional Course (LINC) 2020 (the “Conference”).
CGuard™ EPS will also be featured in three panel discussions and two scientific posters at the Conference. A copy of the
press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
|
InspireMD
Inc.
|
|
|
|
Date:
January 28, 2020
|
By:
|
/s/
Craig Shore
|
|
Name:
|
Craig Shore
|
|
Title:
|
Chief Financial Officer
|
InspireMD (AMEX:NSPR)
Historical Stock Chart
From Mar 2024 to Apr 2024
InspireMD (AMEX:NSPR)
Historical Stock Chart
From Apr 2023 to Apr 2024